RHÖN-KLINIKUM AG  / Key word(s): Agreement/Miscellaneous

18.07.2011 08:30

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.



RHÖN-KLINIKUM AG:

  - Particle therapy development project to be ended

  - Siemens fully compensates RKA for financial disadvantages

  - Revenue and earnings expectations for 2011 remain unchanged

Bad Neustadt a. d. Saale, 18 July 2011

Under a partnership in Marburg, RHÖN-KLINIKUM AG and Siemens AG have been
jointly developing a particle therapy facility. Based on a recent analysis
of the project it has been found, contrary to the original expectations,
that the technology is not yet sufficiently mature as to offer the prospect
of sustained and economically feasible clinical operations within the
foreseeable future. For this reason it has now been mutually decided to end
the project.

RHÖN-KLINIKUM AG and Siemens AG agreed that the financial disadvantages
which arise for RHÖN-KLINIKUM AG will be compensated. At RHÖN-KLINIKUM AG
the discontinuation of the project will result in impairments of EUR 17
million in financial year 2011. Given the undertaking of Siemens AG to make
compensation payments, RHÖN-KLINIKUM AG will incur a non-operative
extraordinary income amount in EBITDA which, on account of the
corresponding impairments, will not have any impact on EBIT and net
consolidated profit.

The originally expected future earnings from the particle therapy facility
are not material in relation to the total output of the RHÖN-KLINIKUM
Group. For that reason, RHÖN-KLINIKUM AG does not expect the
discontinuation of the project to have any materially adverse impact on its
future net assets, financial position and results of operations.

For financial year 2011, RHÖN-KLINIKUM AG continues to expect to generate
revenues of approximately EUR 2.65 billion, a positive operating EBITDA of
EUR 340 million and a net consolidated profit of approximately EUR 160
million, with the last two figures possibly fluctuating within a range of
plus or minus 5%.

The Board of Management

Contact:

Boris Tramm
Head of Investor Relations
RHÖN-KLINIKUM AG
Schlossplatz 1
D-97616 Bad Neustadt a. d. Saale
Tel.: 09771/ 65 - 1318
Fax: 09771/ 99 - 1736
E-mail: boris.tramm@rhoen-klinikum-ag.com


18.07.2011 DGAP's Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


 
Language:     English
Company:      RHÖN-KLINIKUM AG
              Schlossplatz 1
              97616 Bad Neustadt a.d.Saale
              Germany
Phone:        +49 (0)9771 - 65-0
Fax:          +49 (0)9771 - 97 467
E-mail:       rka@rhoen-klinikum-ag.com
Internet:     www.rhoen-klinikum-ag.com
ISIN:         DE0007042301
WKN:          704230
Indices:      MDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), München;
              Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of Announcement                             DGAP News-Service